Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So it's not that we have an excess of capital and cross breakeven and build, but we have several years of execution capability and the ability to manage the expense side to maintain that as we've done here in the middle of the year 2023 |
| A successful study would provide powerful support for G6 adoption and utilization by an increasing number of clinicians |
| When I look at the company, -- you guys have done a pretty good job |
| We also see meaningful recovery of cash by further reducing inventory in the third and fourth quarters that was built up to mitigate supply chain challenges |
| Looking ahead, we believe our long-term growth opportunity is strong based on the uniquely differentiated clinical value propositions of our non-incisional glaucoma treatments as well as launching our refreshed market-leading retina laser platforms |
| While our glaucoma procedure growth rate is currently in the mid-single digits, we believe we have the technology, strategy and team to accelerate our growth from here |
| We think that message is getting out stronger and stronger, and we'll continue to proliferate and people will understand that it's about the dosing that they're delivering and not the device itself or the technique and the procedure itself that's questionable |
| On a topic of dose escalation, 3 different studies totaling 130 patients demonstrated over 30% reduction in IOP, with greater efficacy from slower sweep speeds while delivering the same excellent patient profile -- safety profile |
| But there is a continuum of dosing and escalated dosing to generate better outcomes, better durability and what we're now seeing in the studies that are coming out, maintaining a strong safety profile |
| And so we -- we're successful in having that hold in the marketplace |
| Probe revenue increased by 9% year-over-year, driven by ASP increases and 4% volume growth |
| We remain confident we have the right product and a cost-effective strategy to increase our penetration to the glaucoma market over time |
| So our net number in the mid-single digits we think can improve both more success with newer sites and bringing up to speed on dosing existing happy users so they broaden the patients they use them on and give us a net gross number and then reducing the declines |
| Our current top initiative is educating customers on the updated MicroPulse TLT dosing recommendations to ensure clinicians achieve large IOP reductions and a strong safety profile with our glaucoma treatments, using systems with suite management software, aid surgeons and reliably delivery of the proper dose |
| Our optimism is heightened -- is highlighted by the increasing clinical interest in MicroPulse TLT and the Cyclo G6 platform, as shown by -- with 16 posters presented at the recent World Glaucoma Congress and the multiple levers we're implementing across our substantial user base to drive utilization |
| We believe this process can contribute considerably to growth over time as some of our lower-volume accounts increase their confidence in the procedure outcomes and choose to treat a broader profile of patients with MicroPulse TLT |
| The retina acquisition was fantastic |
| We see a significant opportunity for MP-TLT to provide a clinical and business opportunity for these practices to manage their patients longer by treating patients they would otherwise have referred on |
| And we're confident that, that will ultimately prevail and the growth rates will increase |
| And there's so many patients and specialists in the comprehensive category that we really think good traction or a modest uptick attraction there can really provide some leverage |
| All but one of these was physician-sponsored and represents the broadening clinical interest in MicroPulse TLT |
| These types of findings can provide the confidence for surgeons to pursue higher efficacy with the comfort that safety will be maintained |
| Looking forward to reporting improvements in coming quarters, and thank you for your confidence in the company |
| We remain focused on expense management and operating efficiencies and expect steady improvement in coming quarters as we unwind inventory-related investments and continue to execute on a prudent expense management strategy |
| But we are quite confident that the results that are being achieved will ultimately prevail and the adoption will continue to broaden |
| The positive results of these dose escalation studies has provided IRIDEX the confidence to invest in a larger scale multicenter prospective trial |
| These are necessary steps to retain attention in a crowded glaucoma device space but together represent a larger scale opportunity to become a key treatment choice for the moderate stage glaucoma patient |
| Global adoption of the G6 platform continued as we increased our installed base of systems by 41 units in the quarter |
| While the 15,500 probes sold in the quarter was below our expectations, we're encouraged by progress in several aspects of the business |
| The study I was referring to, the single center study that was performed on prospective 3 dosing arms of about 20 patients each is a key piece of evidence that demonstrates that when you reduce sweep speed, you get better outcomes and progressively better outcomes and a much higher percentage of success |
| Statement |
|---|
| To wrap up, given the softer results in the first half of the year, we are lowering our guidance for fiscal 2023 |
| Revenue in the second quarter declined to $6.9 million from $7.5 million in the prior year period |
| Roughly half of the decline is also due to previously reported loss of royalty revenue in the quarter |
| Our retina product revenue in the second quarter was $6.9 million, a decline of 9% from the prior period |
| This, coupled with generally slower capital purchase cycles can soften demand and our second quarter results exhibited that |
| And I think we did call out particular weakness in the first quarter internationally |
| Our total revenue for the second quarter was $12.9 million, representing a decrease of approximately 7% compared to the second quarter of last year |
| We experienced more cautious customer behavior, which lengthened capital purchasing cycles and softened our systems sales |
| This decline, we believe, is a result of macroeconomic uncertainties and a high interest rate environment |
| The decline in gross margin was a result of lower overhead absorption in the current period |
| As we mentioned on our last call, during the second quarter, we saw lengthening sales cycles for capital equipment amid uncertainty in the rising interest rate macro environment |
| That seems to be stabilizing recently, but remains difficult to forecast rebound timing |
| So when we look at -- to your second question, when you look at, okay, well, you were well below your expectation in the first half of the year and yet you're kind of back to your intended growth rate in the second half of the year |
| And this was our first quarter experiencing reduced royalty income resulting from the previously discussed expiration of licensed patents |
| And we think we can increase the glaucoma growth rate, but it's been a challenge as we've demonstrated in at least the first 2 quarters of this year |
| This driven primarily by reduced royalty revenue from expiration of license patents as previously reported |
| So we do see the supply chain challenges softening |
| As a result, with first half of the year performance below our expectations, we are updating our guidance for the full year 2023 and now expect revenue to be in the range of $55 million to $57 million |
| Other revenue, which includes royalties, services and other legacy products decreased 15% to $2.3 million in the second quarter of 2013 compared to the same period in '22 |
| Part of it is that what we believe is more of a onetime decline of first quarter performance won't be repeated in the subsequent 2 quarters |
Please consider a small donation if you think this website provides you with relevant information